Other investigative agents targeting this pathway include cerdulatinib, a dual inhibitor of JAK and spleen tyrosine kinase (SYK), which is overexpressed in a majority of PTCL [46]. The gene discussed is SYK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.